生物技术公司Adaptive Biotechnologies Corp（股票代码：ADPT）今日盘前股价大涨11.41%，引起投资者广泛关注。这一显著涨幅主要源于公司发布的2025年第一季度财报远超华尔街预期。
根据公司公布的财报，截至2025年3月31日的季度中，Adaptive Biotechnologies调整后每股亏损为0.20美元，明显优于分析师平均预期的0.29美元亏损。同时，公司季度营收同比增长25.2%，达到5244万美元，大幅超越市场预期的4268万美元。这一亮眼业绩表明公司在控制成本和扩大收入方面取得了显著进展。
值得注意的是，尽管当季仍录得2985万美元亏损，但Adaptive Biotechnologies的业绩已连续数个季度超出预期。分析师普遍对公司持积极态度，平均评级为"买入"，12个月目标价中位数为10.00美元。这一业绩改善和乐观前景可能将继续支撑公司股价在未来一段时间内保持强劲表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.